Gary R. MacVicar

3.7k total citations
36 papers, 1.8k citations indexed

About

Gary R. MacVicar is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Gary R. MacVicar has authored 36 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 10 papers in Surgery. Recurrent topics in Gary R. MacVicar's work include Prostate Cancer Treatment and Research (14 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Renal cell carcinoma treatment (7 papers). Gary R. MacVicar is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Renal cell carcinoma treatment (7 papers). Gary R. MacVicar collaborates with scholars based in United States, Switzerland and Vietnam. Gary R. MacVicar's co-authors include Maha Hussain, Kenneth J. Pienta, Debashis Ghosh, Robert Kim, Sooryanarayana Varambally, Rajal B. Shah, Rohit Mehra, Tarek A. Bismar, Ronglai Shen and Mark A. Rubin and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Cell Biology and Cancer.

In The Last Decade

Gary R. MacVicar

36 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary R. MacVicar United States 15 1.0k 523 487 485 325 36 1.8k
G Sauter United States 7 549 0.5× 1.1k 2.1× 298 0.6× 609 1.3× 408 1.3× 11 1.8k
Roxanne Toivanen Australia 15 937 0.9× 597 1.1× 121 0.2× 558 1.2× 374 1.2× 21 1.5k
James P. Solomon United States 14 480 0.5× 438 0.8× 205 0.4× 465 1.0× 263 0.8× 32 1.2k
Atish D. Choudhury United States 16 654 0.6× 892 1.7× 184 0.4× 568 1.2× 472 1.5× 79 1.7k
Yoshio Tomizawa Japan 24 991 1.0× 1.1k 2.1× 118 0.2× 1.1k 2.2× 383 1.2× 72 2.2k
Eijiro Nakamura Japan 21 524 0.5× 1.4k 2.7× 315 0.6× 441 0.9× 1.3k 4.0× 36 2.3k
Jong-Yeon Shin South Korea 17 622 0.6× 967 1.8× 153 0.3× 572 1.2× 529 1.6× 25 1.8k
Bo Gun Jang South Korea 21 355 0.3× 590 1.1× 259 0.5× 466 1.0× 236 0.7× 72 1.2k
Wenlai Zhou United States 13 426 0.4× 1.4k 2.7× 147 0.3× 161 0.3× 252 0.8× 13 1.8k
Franclim R. Ribeiro Portugal 23 921 0.9× 1.1k 2.1× 176 0.4× 302 0.6× 628 1.9× 38 1.8k

Countries citing papers authored by Gary R. MacVicar

Since Specialization
Citations

This map shows the geographic impact of Gary R. MacVicar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary R. MacVicar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary R. MacVicar more than expected).

Fields of papers citing papers by Gary R. MacVicar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary R. MacVicar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary R. MacVicar. The network helps show where Gary R. MacVicar may publish in the future.

Co-authorship network of co-authors of Gary R. MacVicar

This figure shows the co-authorship network connecting the top 25 collaborators of Gary R. MacVicar. A scholar is included among the top collaborators of Gary R. MacVicar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary R. MacVicar. Gary R. MacVicar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Flaig, Thomas W., Catherine M. Tangen, Siamak Daneshmand, et al.. (2023). Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). European Urology. 84(3). 341–347. 9 indexed citations
3.
Carthon, Bradley Curtis, Se Eun Kim, David F. McDermott, et al.. (2023). Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808. Clinical Genitourinary Cancer. 21(5). 546–554. 1 indexed citations
4.
Jun, Tomi, Noah M. Hahn, Guru Sonpavde, et al.. (2022). Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma. The Oncologist. 27(6). 432–e452. 3 indexed citations
5.
Flaig, Thomas W., Catherine M. Tangen, Siamak Daneshmand, et al.. (2022). SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up.. Journal of Clinical Oncology. 40(6_suppl). 536–536. 5 indexed citations
6.
Flaig, Thomas W., Catherine M. Tangen, Siamak Daneshmand, et al.. (2021). A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clinical Cancer Research. 27(9). 2435–2441. 58 indexed citations
7.
8.
McCune, Steve, Leora Horn, Ivor Percent, et al.. (2019). EP1.12-06 New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting. Journal of Thoracic Oncology. 14(10). S1018–S1019. 1 indexed citations
9.
Goldkorn, Amir, Melissa Plets, Neeraj Agarwal, et al.. (2016). Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology. 34(15_suppl). 11516–11516. 4 indexed citations
10.
Dreicer, Robert, David B. MacLean, Ajit Suri, et al.. (2014). Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 20(5). 1335–1344. 34 indexed citations
11.
MacVicar, Gary R. & Maha Hussain. (2013). Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer. Current Opinion in Oncology. 25(3). 252–260. 30 indexed citations
12.
Grivas, Petros, Neeraj Agarwal, Arlene O. Siefker‐Radtke, et al.. (2012). Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC).. Journal of Clinical Oncology. 30(15_suppl). 4506–4506. 11 indexed citations
13.
Atchison, Elizabeth A., John Eklund, Lili Wang, et al.. (2010). A Pilot Study of Denileukin Diftitox (DD) in Combination With High-dose Interleukin-2 (IL-2) for Patients With Metastatic Renal Cell Carcinoma (RCC). Journal of Immunotherapy. 33(7). 716–722. 14 indexed citations
14.
MacVicar, Gary R., et al.. (2009). An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 27(15_suppl). 5062–5062. 11 indexed citations
15.
MacVicar, Gary R., Filippo Greco, James A. Reeves, et al.. (2008). 209 POSTER An open-label, multicenter, phase 1/2 study of AT-101 in combination with docetaxel and prednisone in men with hormone refractory prostate cancer. European Journal of Cancer Supplements. 6(12). 66–66. 2 indexed citations
16.
Hussain, Maha, Gary R. MacVicar, Daniel P. Petrylak, et al.. (2007). Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/ neu –Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial. Journal of Clinical Oncology. 25(16). 2218–2224. 292 indexed citations
17.
MacVicar, Gary R. & Maha Hussain. (2005). Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes. Cancer Chemotherapy and Pharmacology. 56(S1). 69–77. 3 indexed citations
18.
Henry, N. Lynn, Gary R. MacVicar, & Maha Hussain. (2005). Management of patients with muscle-invasive and metastatic bladder cancer.. PubMed. 19(10). 1333–42; discussion 1342, 1347, 1350 passim. 5 indexed citations
19.
MacVicar, Gary R. & Kenneth J. Pienta. (2004). Testicular cancer. Current Opinion in Oncology. 16(3). 253–256. 4 indexed citations
20.
Dubreuil, Ronald R., et al.. (1997). Segregation of Two Spectrin Isoforms: Polarized Membrane-binding Sites Direct Polarized Membrane Skeleton Assembly. Molecular Biology of the Cell. 8(10). 1933–1942. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G Sauter Breakdown of academic impact, for papers by Roxanne Toivanen Breakdown of academic impact, for papers by James P. Solomon Breakdown of academic impact, for papers by Atish D. Choudhury Breakdown of academic impact, for papers by Yoshio Tomizawa Breakdown of academic impact, for papers by Eijiro Nakamura Breakdown of academic impact, for papers by Jong-Yeon Shin Breakdown of academic impact, for papers by Bo Gun Jang Breakdown of academic impact, for papers by Wenlai Zhou Breakdown of academic impact, for papers by Franclim R. Ribeiro
Rankless by CCL
2026